



**SUPPLEMENTARY FIG. S6.** Local adaptive immune response after primary perinatal rAAV2/5 administration or readministration in adult life. Bronchoalveolar lavage fluid (BALF) samples were analyzed 1 month postreadministration after initial fetal and neonatal rAAV2/5 delivery ( $1.5 \times 10^{10}$  GC of rAAV2/5-FLUC per animal). In addition, samples from animals that received only a single dose as fetus or neonate (i.e., non-readministration controls), as well as samples from negative age-matched mice and adult control mice that received a single vector dose, were analyzed in parallel. **(A)** Analysis of the percentage of B cells ( $B220^+$ ) and **(B)** Tregs ( $CD4^+Foxp3^+$ ) in the total lymphocyte population in BALF. The cells were incubated with fluorochrome-labeled monoclonal antibodies to B220, CD4, and Foxp3 and subjected to FACS analysis. Mean  $\pm$  SEM, comparisons for each pair using Student *t* test. *Abbreviations:* fetal or neonatal, non-readministration controls for the fetal and neonatal group 4 months after perinatal rAAV2/5 delivery; Fetal-R or Neonatal-R, initial fetal or neonatal vector delivery followed by readministration at 3 months and BALF collection at 4 months; Adult ctrl, adult control mice that received a single vector dose, BALF collection 1 month postinjection.